Vitrification Market

Market Overview The global vitrification market is set for substantial expansion, growing from USD 9.82 billion in 2025 to USD 23.45 billion by 2031, exhibiting a 15.61% compound annual growth rate. This market centers on a cryopreservation technique that employs ultra-rapid cooling and concentrated cryoprotectants to convert reproductive cells into a stable, glass-like state, effectively preventing the formation of damaging ice crystals. Key factors driving this growth include the rising worldwide prevalence of infertility and the increasing trend towards delayed parenthood, which together stimulate the demand for oocyte and embryo banking. Furthermore, vitrification's superior post-thaw survival and higher pregnancy rates, compared to traditional slow-freezing methods, have established it as the preferred standard in assisted reproductive technology clinics globally. Despite these strong growth indicators, the market faces a considerable challenge due to the high financial burden of vitrification procedures and the lack of standardized insurance reimbursement in many regions, which subsequently restricts patient accessibility. Nevertheless, evidence suggests continued adoption; for instance, the Human Fertilisation and Embryology Authority reported in 2025 that frozen embryo transfer cycles in the United Kingdom increased by 24% over the preceding four-year period, underscoring the dominant shift towards cryopreservation in fertility treatments. Market Driver The foremost drivers propelling the vitrification market are the rising global prevalence of infertility and the corresponding increase in demand for Assisted Reproductive Technologies (ART). As demographic shifts lead more individuals to delay family building, the natural conception window narrows, creating a critical need for advanced interventions to safeguard future reproductive potential. This trend is underscored by the United Nations' May 2025 report, which indicated that the global fertility rate had decreased to 2.2 births per woman in 2024, emphasizing the urgency for effective preservation solutions. Consequently, fertility clinics are increasingly favoring vitrification over slow freezing due to its superior survival rates, directly boosting the volume of cryopreservation procedures and the associated consumption of specialized media and devices. Concurrently, the market is experiencing significant expansion driven by the growing social acceptance of elective egg freezing, frequently supported by evolving corporate reimbursement policies and shifting career priorities. This surge in 'social freezing' is clearly reflected in recent clinical activity; according to the Society for Assisted Reproductive Technology (SART) in 2025, data showed that 39,269 oocyte banking cycles for fertility preservation were performed in the United States during the 2023 reporting year. This increasing volume of preservation cycles reinforces the broader financial health of the sector, a trend exemplified by Vitrolife Group's March 2025 announcement of a 10% increase in sales of consumables in local currencies for the full year 2024, reflecting robust demand for procedure-related products. Market Challenge The growth of the Global Vitrification Market is significantly constrained by the substantial financial burden of its procedures and the lack of standardized insurance reimbursement. While the clinical benefits of vitrification are well-established, the technology's complex laboratory protocols and specialized storage requirements escalate operational costs. In many regions, fertility preservation is classified as an elective service rather than a medical necessity, forcing patients to cover the entire financial cost out-of-pocket. This economic barrier limits the market's reach to predominantly high-income demographics, preventing widespread adoption among the broader population that requires these crucial services. Consequently, clinics face restricted growth in patient volume, as the prohibitive entry cost deters a significant portion of potential clients from initiating treatment. This financial challenge is quantitatively supported by recent industry findings regarding the cost of care. According to the American Society for Reproductive Medicine, in 2024, the average cost for a single in vitro fertilization cycle in the United States ranged between $12,000 and $15,000, a figure that excludes the substantial expense of necessary medications. Such high expenditures, often without adequate insurance support, directly reduce the demand for vitrification services, thereby impeding the market's ability to achieve its full global potential. Market Trends A key trend transforming the market is the accelerated adoption of automated vitrification platforms, which critically address the need for standardization and reproducibility in cryopreservation procedures. Unlike manual techniques, which are susceptible to inter-operator variability, automated systems provide precise control over cooling rates and cryoprotectant exposure, thereby significantly reducing the risk of ice crystal formation and enhancing specimen safety. This industry shift towards high-tech hardware solutions is quantitatively demonstrated by recent financial performance in the sector; Vitrolife Group's January 2025 'Fourth Quarter and Full Year Report 2024' reported a 16% increase in sales in local currencies within its Technologies business area, underscoring the rapid uptake of advanced equipment by clinics aiming to optimize laboratory workflows. Concurrently, the integration of artificial intelligence (AI) for process optimization is enhancing the efficacy of vitrification through predictive analytics and non-invasive assessment tools. Machine learning algorithms are now being utilized to evaluate oocyte and embryo quality prior to freezing, allowing clinicians to customize protocols based on specific morphological biomarkers that predict post-thaw survival. This data-driven approach maximizes the potential for successful pregnancy while minimizing the number of cycles required for patients. According to the Journal of IVF-Worldwide in May 2025, an article titled 'Global Trends in the Use of Artificial Intelligence in Reproductive Medicine' revealed that the usage of AI tools among fertility specialists had risen to approximately 53% by 2025, confirming the technology's growing role in refining preservation strategies. Key Market Players * Vitrolife Inc. * Genea Biomedx inc. * NidaCon International AB * Minitube International * IMV Technologies Group * The Cooper Companies, Inc. * FUJIFILM Corporation * Biotech, Inc. * Kitazato Corporation * Shenzhen VitaVitro BiotechAGEN N.V. Report Scope In this report, the Global Vitrification Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Vitrification Market, By Specimen * Oocytes * Embryo * Sperm # Vitrification Market, By End-use * IVF Clinics * Biobanks # Vitrification Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Vitrification Market. Available Customizations: Global Vitrification Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).